Interference 102,760
1. A method for treatment of sleep apneas
comprising
administration of a therapeutically effective regimen of
a Formula I azapirone compound or a pharmaceutically[2]
effective acid addition salt thereof to a patient in need
of such treatment . . . .
February 12, 1991 -- Schwimmer filed Application
07/657,332, as a continuation of Application 07/478,820.
May 3, 1991 -- Dement, Rosekind, and Schwimmer (hereafter
Dement et al.) filed Application 07/695,325, as a
continuation-in-part of Applications 07/479,803 and
07/657,332. Original Claim 1 of Application 07/695,325 reads
in pertinent part:
1. A method for treatment of sleep apneas
comprising
administration of a therapeutically effective amount of a
Formula I azapirone compound or a pharmaceutically[3]
effective acid addition salt thereof to a patient in
need of such treatment . . . .
January 10, 1992 -- The Notice of Declaration of
Interference 102,760 mailed January 10, 1992 (Paper No. 2),
accorded senior party Dement et al. benefit of the February
12, 1990, filing date of Application 07/478,820; the February
2 The azapirone compounds of Rapoport’s Formula I include
buspirone. Dependent Claim 6 is directed to buspirone.
3 The azapirone compounds of Dement et al. Formula I
include buspirone. Dependent Claim 7 is directed to buspirone.
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007